Originally posted on 5/28/2013
ASAP Corporate Member Servier, a privately run French research-based pharmaceutical company concentrating on cardiovascular disease treatments in Europe and emerging markets, has expanded its alliance with miRagen Therapeutics, Inc., a biopharmaceutical company developing microRNA-based therapeutics. The two companies have just announced that Servier has elected to add a new target as part of its existing agreement for advancing the research, development, and commercialization of microRNA-based drug candidates for the treatment of cardiovascular disease. Servier and miRagen now have three microRNA programs under development.
“Our selection of a third target is indicative of the strength of our partnership with miRagen, as well as our shared commitment to develop microRNA-based therapies for the treatment of cardiovascular disease,” said Dr. Jean-Paul Vilaine, head of Servier’s Cardiovascular Research Unit. “We look forward to our continued collaboration to advance promising drug candidates.” And Dr. Jean-Philippe Seta, Servier’s CEO, said, “Micro-RNA is now the gateway to acting at the deepest level of gene expression regulation, with exciting prospects of major developments in the treatment of cardiovascular disease.”
“The achievement of this milestone further validates the potential of miRagen’s platform in the development of disease-modifying drug candidates,” said William S. Marshall, Ph.D., president and CEO of miRagen. “We remain deeply committed to the discovery and advancement of microRNA-based therapeutics, and we anticipate that our partnership with Servier will yield life-changing treatment options for patients in need.”
In October 2011, miRagen entered into a strategic alliance with Servier with the goal of advancing microRNA-based therapies in cardiovascular disease. The alliance initially included two named targets (miR-208 and miR-15/195) and granted Servier the right to add one additional target. Under the terms of the agreement, miRagen received an upfront payment in 2011, is scheduled to receive a target selection payment in 2013, and additional research and development milestones per target. miRagen is also eligible to receive commercial milestones and royalties on the sale of products under the alliance. Servier will finance the research, development, regulatory approval, and commercialization costs of the three product candidates. miRagen retains all commercialization rights in the United States and Japan, and the option to cosponsor any Phase III programs in the event that miRagen, alone or together with a partner, should seek marketing approvals for any of the targets in those countries.
This post has not been tagged.